Krsnaa Diagnost. (KRSNAA)
StalwartFairStock Score: 37/100 — MIXED
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹575.3 |
| Market Cap | ₹1,866.2 Cr |
| P/E Ratio | 18.62 |
| ROCE | 12.52% |
| ROE | 9.47% |
| Dividend Yield | 0.35% |
| Profit Growth | -19.13% |
| Debt/Equity | 0.55 |
| Sales Growth | 21.3% |
| Promoter Holding | 27.11% |
| 52-Week Range | ₹480 — ₹838 |
| Sector | Healthcare Services |
| Book Value | ₹302.22 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Krsnaa Diagnost is not a business that would get me excited. With a market cap of ₹2,061 Cr and a P/E of 25.65, the market is paying a full price for a company whose sales have shrunk by 3.47% and profits are down 23.66%. In the latest quarter, sales were ₹159 Cr and net profit ₹16 Cr, a margin of about 10%. But the trailing P/E suggests investors are assuming a rapid return to growth. I don't see evidence for that. The Piotroski F-Score of 3/9 is a serious red flag, indicating weak operating efficiency and deteriorating fundamentals. Graham would demand a margin of safety; at 2.33 times book with a 9.47% ROE, you are paying a premium for subpar returns. Debt-to-equity of 0.31 is manageable, and ROCE at 12.52% is okay, but not outstanding. Also, promoter holding of 27.11% is low; I like my captains to have a large ownership stake. The dividend yield of 0.43% offers no support. This looks like a slow grower at best, possibly a value trap if performance doesn't improve. I would need to see clear signs of revenue stabilization and an improving F-score before considering a nibble. As Benjamin Graham said, price is what you pay, value is what you get. Here, I'm not convinced value is present.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer